Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Apple Turns 50: From Garage Startup to AI Crossroads 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
DUBLIN, Ireland, Dec. 22, 2016 -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that it plans to present at the 35th Annual J.P. Morgan Healthcare Conference. Timothy P. Walbert, chairman, president and chief executive officer, will present at 7:30 a.m. Pacific Time on January 10, 2017.
The presentation will be webcast live and may be accessed by visiting Horizon's website at http://ir.horizon-pharma.com. A replay of the webcast will be available following the event.
About Horizon Pharma plc
Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. Horizon Pharma markets 11 medicines through its orphan, rheumatology and primary care business units. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter or view careers on our LinkedIn page.
Contacts: Investors: Tina Ventura Senior Vice President, Investor Relations [email protected] U.S. Media: Geoff Curtis Senior Vice President, Corporate Communications [email protected] Ireland Media: Ray Gordon Gordon MRM [email protected]
